A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with untreatable advanced hepatocellular carcinoma - the CanHep study

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514049-13-02

Enrollment

Registered

2024-10-29

Start date

Unknown

Completion date

Unknown

Last updated

2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients with untreatable hepatocellulare carcinoma

Brief summary

To study objective response rate (ORR) of cannabis oil (THC10% / CBD5%) in untreatable advanced HCC patients by assessing RECIST31 and mRECIST32 criteria on imaging at 9 months after starting cannabis oil.

Interventions

DRUGCANNABIDIOL

DRUGDRONABINOL

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To study objective response rate (ORR) of cannabis oil (THC10% / CBD5%) in untreatable advanced HCC patients by assessing RECIST31 and mRECIST32 criteria on imaging at 9 months after starting cannabis oil.	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026